Investigator studied current treatment patterns and attrition rates in metastatic clear cell renal cell carcinoma using a large, US nationwide cohort.

The flywheel for building, design and technology innovation. That is TKI Construction and Technology. By enabling industry, knowledge institutions, government ministries and umbrella organisations to ...

Ehlers, MD, shares results from the phase 1 HELIOS study investigating OTX-TKI for the treatment of nonproliferative diabetic retinopathy. The study examined a single injection of OTX-TKI ...

Exelixis’ lead drug Cabometyx maintains its status as the leading tyrosine kinase inhibitor (TKI) for the treatment of renal cell carcinoma (RCC) in both the frontline immuno-oncology (IO ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

“However, many patients still receive TKI or ICI monotherapy in this setting.” The investigators had no information on patients’ clinical profile or socioeconomic status, limiting analyses ...